Member Info for EmeraldCarrots

Hello.

Correction. Spelling errors and "CCT" accidently used instead of CTC (Circulating tumour cell).

Https://www.ft.com/content/d146dc71-3060-4bc7-bb1b-d60c24193e14

Grail offer the Galleri Test that helps screen for cancer. From a search on google for "what does the galleri test do":-

"The Galleri test analyzes cfDNA fragments to detect abnormalities in methylation patterns that could indicate the presence of cancer. Galleri has been trained on the largest known methylation database to identify patterns common to many cancers.". This is a state of the art test, currently available to help find out if a person has cancer.

Once a person has in their blood "circulating tumour cells" (CTC's) obviously they already have cancer and have had for quite some time as CCT's don't come off the original tumour in the early stages (I think until around stage 4?). Angle's Parsortix machine can catch CTC's, 99% of which are LIVE and intact, ideal for testing in the same way the cfDNA fragments are. Angle are suggesting that similar tech is applied to test CTC's which would give valuable additional information about the state of a persons cancer as treatment progresses. So a test before any treatment to establish the base line. Then tests (every few months?) during treatment. The test would be both to monitor the cfDNA fragments generally in the blood AND to test the CTC's. Both tests to obtain all the information available about the treatments effect. The aim being to find out as soon as possible if the treatment is starting to work, or is having zero effect. If zero effect clearly the treatment could be stopped and another one tried. Receiving treatment that IS NOT WORKING is obviously very, very important to know. This is what Angle are suggesting. Makes sense to me.

All IMHO.

Https://www.ft.com/content/d146dc71-3060-4bc7-bb1b-d60c24193e14

Grail offer the Galleri Test that helps screening for cancer. From search on google for "what does the galleri test do":-

"The Galleri test analyzes cfDNA fragments to detect abnormalities in methylation patterns that could indicate the presence of cancer. Galleri has been trained on the largest known methylation database to identify patterns common to many cancers.". This is a state of the art test, currectly available.

Once a person has in their blood "circulating tumour cells" (CTC's) obviously they already have cancer. Angle's machine can catch CCT's, 99% of which are LIVE and intact, ideal for testing in the same way the cfDNA fragments are. Angle are suggesting that similar tech is applied to test CCT's which will give valuable additional information about the state of a persons cancer as treatment progresses. So a test before any treatment to extablish the base line. Then tests (every few months?) during treatment. The test would be both to monitor the cfDNA fragments generally in the blood AND to test the CCT's to obtain all the information available about the treatments effect. The aim being to find out as soon as possible if the treatment is starting to work, or is having zero effect. If zero effect clearly the treatment could be stopped and another one tried. This is what Angle are suggesting. Makes sense to me.

All IMHO.

I suppose even if the flow rate if just a few hondred barrels per day they would not know that until the lower level is tested!

From RNS dated 11th March:-

"Two flow tests are scheduled, one each in the Upper SFS and SMD-B reservoirs, with each frac and flowback operation expected to take approximately ten days.".

"The Company looks forward to providing an update on completion of the Upper SFS flow test.".

Approximately 10 days from11th is today, the 21st.

TwoGood2Die.

"Probably because Illumina have their own solution and no one is buying any Parsortix machines because they are not FDA approved!".

===============================

Lying again I see.

"Illumina have their own solution". No they don't, not as good as Parsortix. Lie Nr. 1.

"no one is buying any Parsortix machines". Lie Nr. 2.

"they are not FDA approved!". They are approved for use with Breast Cancer in the USA as you undoubtedly know. Lie nr. 3. Shows the sort of person you are.

Also they do not have to be approved for cancer research. Lie nr 3a.

Are you capable of posting a single sentence that has any truth in it at all? I suspect not.

Surely no-one on here listens to anything you say considering your track record.

All IMHO.

Bantham.

You say " Newland has a track record of failure.".

Presumably you mean the failure to sell anything like the amount of Parsortix machines originally expected?

Last year, I think that without any assays to go with it (so the client had to do them) or standardised staining kits the expected sales of the machine were totally unrealistic. Now of course Angle have developed some assays and staining kits that they offer to sell with the machine making it more user friendly. Also they offer a service from their lab which uses in house Parsortix machines to catch and analyse circulating tumour cells (blood sample sent in from client) in many, many different ways. Including the molecular analysis that Mr Newland described as "a game changer".

Indeed this side is extremely interesting and, at least at the moment, I too believe the molecular analysis side really could be a "game changer" for Angle. Seems to make sense. Companies like Illumina and Thermo Fisher already sell machines that analyse a standard blood sample for so called "actionable DNA variants". If found these already known DNA varients can give important information to the clinician about the cancer helping treatment decision making. Now as we know Angle have made the breakthrough that using the same process on circulating tumour cells (ctc's) that Parsortix can catch can give important ADDITIONAL information for the clinician. Presumably this is accurate and totally up to date information as the circulating tumour cell will have come from the cancer tumour looking to seed itself somewhere else in the body. As Mr Newland has said these Companies could offer Parsortix to their existing and new clients who may well want this additional information to get all of the available information, the "Full Picture". Obviously Mr Newland could do some sort of deal with one or more of these companies and I don't see why they would not be interested.

All IMHO.

My impression of Mr Newland is he's not one to sell anything on the cheap. Possibly quite the opposite in fact. I have done more reseach on the Parsortix system. It ticks all the boxes. Other products can catch circulating tumour cells but Parsortix is quick, 99% of the cells collected are live, intact and not contaminated by the very system used to catch them. You can't get a better circulating cancer tumour cell to test, period. Angle only need half a dozen contracts on the assay side and things will be a lot different. And that does not include the distinct possibility one or more of the molecular analysis Co's will want some sort of deal, maybe even buy them out. We can be sure of one thing. Newland won't do a deal on the cheap. I just hope he does not ask so much no-one will bite.........

All IMHO.

Thanks.

Any time, could be today.

You serious?

Nothing changes. The official RNS is the only thing you can be sure of.

And we are awaiting it.

Then the next flow test to wait on.....

Note there are two flow tests. We are awaiting the result of the 1st one. 2nd one follows, is it 10 days later?

Won't be long until news. Bound to get some oil I think......... just how much.

In fact why would they NOT be interested in buying Angle Plc? Same goes for any Co. that currently offers molecular analysis of blood.

Illumina (and 50 or so others like Thermo Fisher) have the hardware and software to identify actionable DNA variants.

Their systems are used to do this every day, but from a general blood sample. DNA varients can be targeted by modern cancer treatments. Angle's Parsortix system gives their clients the opportunity (if they have a parsortix machine) to do the same with the circulating tumour cells in addition to the general blood. Parsortix can catch these from the same standard blood sample. See Angle Plc's RNS announcements 4th and 20th Jan this year. More accurate than sampling general blood then. 99% of the circulating tumour cells Parsortix can catch are ***LIVE and intact***. I don't see how you could get a better sample of the tumour to test. So is it not the case that testing circulating tumour cells to find actionable DNA variants is the next step forward??

Surely offering this addition would increase Illumina's sales (or Thermo Fishers etc...). Seems obvious to me.

We know Angle have talked to Illumina about the results of testing the CTC's. I suspect they will have talked to Thermo Fisher and any other Company in the same field by now. One is bound to do some sort of deal IMHO. Just a metter of time. From Illumina's web site:-

https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf

All IMHO.

Gulp!

Moab.

"No, Carrot, I am not a troll. I just find pointless repetition rather irritating, (as at 10.40 and 10.41) as I suspect do others. I also prefer posts to be accurate, and to the point. I have read the .pdf carefully which I why I made my post @ 10.08. I am not trying to provoke anything beyond an explanation. I repeat; what was your point in drawing attention to this.pdf?".

========================================

Are you sure you are not having a laugh? I honestly think you are. Or you want me to explain the relevance because you have a long position and don't think some on here would understand it? Is that it??

The Illumina web page (see link below) is entitled "Liquid Biopsy and NGS: Driving translational clinical research to the next level". The ***"NEXT LEVEL"***. You do know what a liquid biopsy is don't you? You simply must know that Angle's machine can catch a single LIVE intact circulating tumour cell (ctc) from a standard blood sample. 99% caught using their Parsortix machine are LIVE and intact, ideal for analysing. Other competing systems often kill and/or and damage the ctc.

Angle Plc's RNS announcements of 4th and 20th Jan 2024 say they found "actionable DNA variants" in the circulating tumour cells that could not be found in the same persons CtDNA blood plasma test (general blood test to find, then test for actionable CtDNA). Even though both tests were done using ONE BLOOD SAMPLE FROM THE SAME PERSON. Exactly the same NGS methods were used. According to Angle that was previously either unknown, or I think had been noticed in some study's but it's significance not appreciated. Does in not occur to you that "the next level" may well, no, is likely to include analysing the cct's for "actionable DNA variants"? Actionable DNA variants being DNA that can be ****targeted by modern drugs to help cure cancer****.

Some extracts from the Illumina article:-

"Next-generation sequencing (NGS) methods enable highly sensitive and specific detection of known mutations."

As per Angle's RNS's they found some of these in the CtC's.

"More recently, comprehensive assays are being developed to analyse a wider range of candidate genes and variant types for new tumour’s that do not have known variants. As these methods evolve, ctDNA analysis for various applications such as screening, therapy selection, monitoring, and identification of therapy resistance is gaining prominence as a method for monitoring disease state."

https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf

All IMHO.

Are you a "troll", which I understand is someone who likes to annoy other people?

I'm not going to reply to you provocation. People can read this Illumina page about liquid biopsies and judge for themselves. Have you even read it? LOL!

https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf

U sure Illumina won't bid for Angle Plc?!!!!

From Illumina's web site:-

https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf

Hello.